Description: Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Home Page: www.prometheusbiosciences.com
RXDX Technical Analysis
9410 Carroll Park Drive
San Diego,
CA
92121
United States
Phone:
858 684 1300
Officers
| Name | Title |
|---|---|
| Mr. Mark C. McKenna | Pres, CEO & Chairman |
| Dr. Keith W. Marshall M.B.A., MBA, Ph.D. | Chief Financial Officer |
| Mr. Mark Stenhouse | Chief Operating Officer |
| Dr. Allison Luo M.D. | Chief Medical Officer |
| Dr. Olivier Laurent Ph.D. | Chief Scientific Officer & Head of R&D |
| Ms. Noel Kurdi | VP of Investor Relations & Communications |
| Mr. Timothy K. Andrews Esq. | Gen. Counsel & Sec. |
| Ms. Nori Ebersole | Chief People Officer |
| Dr. Thierry Dervieux DABCC, Ph.d., Pharm.d. | Chief Devel. Officer of Diagnostics & Medical Laboratory Director |
| Mr. Chris Doughty | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 19.8767 |
| Price-to-Sales TTM: | 627.821 |
| IPO Date: | 2021-03-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 72 |